This article will discuss technological innovations in nasal delivery devices that may lead to commercial success.
Nasal drug delivery is an attractive, growing niche, in part because devices can confer added value compared to generics and clinically are able to deliver fast onset with non-invasive administration of systemically-acting drugs, including biologics. Development efforts are focusing on reformulation and repackaging of successful, existing systemic drugs. Regulatory pathways in Europe and in the US are increasingly clear. This author foresees increased penetration by preservative-free products. Modest investments and relatively short development times are conducive to early product launches.